Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRX NASDAQ:GALT NASDAQ:PHAS NASDAQ:SPRO NASDAQ:TLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKRXAkorn$0.19$0.09▼$5.46$3.60M0.959.60 million shs1.19 million shsGALTGalectin Therapeutics$5.00+1.5%$3.94$0.73▼$6.55$315.82M0.86401,406 shs31,054 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSPROSpero Therapeutics$2.02-0.7%$2.11$0.51▼$3.22$113.40M1.471.72 million shs34,306 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKRXAkorn0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics+2.50%+9.33%+20.00%+103.31%+77.62%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SPROSpero Therapeutics+1.50%+7.98%+8.56%-29.51%+52.63%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKRXAkorn$0.19$0.09▼$5.46$3.60M0.959.60 million shs1.19 million shsGALTGalectin Therapeutics$5.00+1.5%$3.94$0.73▼$6.55$315.82M0.86401,406 shs31,054 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsSPROSpero Therapeutics$2.02-0.7%$2.11$0.51▼$3.22$113.40M1.471.72 million shs34,306 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKRXAkorn0.00%0.00%0.00%0.00%0.00%GALTGalectin Therapeutics+2.50%+9.33%+20.00%+103.31%+77.62%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SPROSpero Therapeutics+1.50%+7.98%+8.56%-29.51%+52.63%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKRXAkorn 0.00N/AN/AN/AGALTGalectin Therapeutics 3.00Buy$6.0020.12% UpsidePHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ASPROSpero Therapeutics 2.50Moderate Buy$5.00148.14% UpsideTLCTaiwan Liposome 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKRX, SPRO, GALT, TLC, and PHAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKRXAkorn$682.43M0.00N/A0.19$1.86 per share0.00GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SPROSpero Therapeutics$47.98M2.36N/AN/A$0.85 per share2.37TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKRXAkorn-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/AGALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest AKRX, SPRO, GALT, TLC, and PHAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKRXAkornN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKRXAkorn0.090.500.32GALTGalectin TherapeuticsN/A1.431.43PHASPhaseBio PharmaceuticalsN/A0.470.47SPROSpero TherapeuticsN/A3.973.97TLCTaiwan Liposome0.673.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKRXAkorn64.03%GALTGalectin Therapeutics11.68%PHASPhaseBio Pharmaceuticals49.02%SPROSpero Therapeutics25.60%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipAKRXAkorn3.90%GALTGalectin Therapeutics50.10%PHASPhaseBio Pharmaceuticals9.90%SPROSpero Therapeutics5.50%TLCTaiwan LiposomeN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKRXAkorn2,227133.15 millionN/AOptionableGALTGalectin Therapeutics964.06 million31.97 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableAKRX, SPRO, GALT, TLC, and PHAS HeadlinesRecent News About These CompaniesThe Wyatt Sicks Retain Tag Team Championship At WWE SummerSlam 2025 In Wild TLC MatchAugust 4, 2025 | msn.comTop tag team gets booed at SummerSlam 2025 after winning the TLC Title matchAugust 4, 2025 | sportskeeda.comSThe Hardy Boyz Appear At WWE SummerSlam Ahead Of Six-Way TLC MatchAugust 4, 2025 | si.comSWWE HOFer Bully Ray Has Two Words For SummerSlam 2025 TLC Match Stars: Good LuckAugust 4, 2025 | msn.comUnexpected Chaos Erupts As 12 Wrestlers Pay Homage In TLC MatchAugust 4, 2025 | thesportster.comTWyatt Sicks Pull Down WWE Tag Titles In Crowded TLC Match At SummerSlam 2025 Night 2August 4, 2025 | msn.comWWE SummerSlam 2025 Night 2 Results: Wyatt Sicks Retain in Brutal TLC Match, But Crowd Doesn’t Buy InAugust 4, 2025 | athlonsports.comAWyatt Sicks Retain WWE Tag Team Championships In TLC Match At SummerSlamAugust 3, 2025 | fightful.comFKIOXIA samples next-gen 512Gb TLC BiCS FLASH storage solutionsJuly 29, 2025 | tweaktown.comTUnbelievable TLC Title Match Set for SummerSlam 2025July 26, 2025 | msn.comTrusted care with a personal touch: TLC Pharmacy marks over a decade of serviceJuly 19, 2025 | discovermoosejaw.comDT-Boz Explains How TLC Bought Back The Rights To Their Name Along With The Amount They Paid For Each LetterJuly 19, 2025 | msn.comTLC Spent $3M To Reclaim Group Name Ownership From PebblesJuly 19, 2025 | msn.comSpinoff of TLC’s hit show 90 Day Fiance features ShreveporterJuly 17, 2025 | msn.comTLC Community Center makes big move with a little help from old friendsJuly 15, 2025 | johnsoncitypress.comJTLC Wellness: The Upside of Life with Pets: Child Development and Family ConnectionJuly 15, 2025 | msn.comDiggin’ on you: TLC tops off the Big E’s concert lineupJuly 15, 2025 | msn.comHere’s What TLC Isn’t Telling You About 'Sister Wives' Season 20July 11, 2025 | aol.comATLC’s ‘My Big Fat Fabulous Life’: Whitney undergoes womb cleansing ceremonyJuly 9, 2025 | msn.comTLC Reality Star, 27, Accused of Verbal Abuse in Shocking Audio Shared by ExJuly 9, 2025 | au.lifestyle.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 2025AKRX, SPRO, GALT, TLC, and PHAS Company DescriptionsAkorn NASDAQ:AKRXAkorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Galectin Therapeutics NASDAQ:GALT$5.00 +0.08 (+1.52%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Spero Therapeutics NASDAQ:SPRO$2.02 -0.02 (-0.74%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Taiwan Liposome NASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
